City

Clinical trials near New York, United States

Active studies with a listed research site in New York, United States.

59active studies

37recruiting now

12countries represented

50largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 1

Graded Insulin Suppression Test P&F

Insulin Resistance, HyperinsulinemiaCondition

Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia), Insulin regular, 32 mU/m2/min (hyperinsulinemia)Treatment

United States1 locations

Columbia UniversitySponsor

Updated 2026-09-08 · NCT06592261See eligibility →

Recruiting nowPhase 3

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Obesity, Overweight and/or ObesityCondition

PF-08653944, PlaceboTreatment

Brazil, Canada50 locations

PfizerSponsor

Updated 2026-09-04 · NCT07595549See eligibility →

Recruiting nowPhase 4

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Psoriasis, Overweight or ObesityCondition

TirzepatideTreatment

United States39 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06857942See eligibility →

Recruiting nowPhase 1

Alpelisib Challenge Test (ACT)

Insulin Resistance, Type 2 DiabetesCondition

Alpelisib 300 mg, Alpelisib Challenge Test (ACT): Mixed Meal Tolerance Test (MMTT) after taking alpelisibTreatment

United States1 locations

Columbia UniversitySponsor

Updated 2026-09-03 · NCT07778524See eligibility →

Recruiting nowPhase 2

Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)

Overweight, Overweight and ObesityCondition

Counseling, Text MessagesTreatment

United States1 locations

Memorial Sloan Kettering Cancer CenterSponsor

Updated 2026-09-02 · NCT05770570See eligibility →

Recruiting nowPhase 2

GLP-1R Agonist Treatment for Opioid Use Disorder

Opioid Use Disorder, Opioid Abuse and AddictionCondition

Semaglutide Pen Injector, PlaceboTreatment

United States4 locations

Milton S. Hershey Medical CenterSponsor

Updated 2026-08-28 · NCT06548490See eligibility →

Recruiting nowPhase 3

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Obesity or OverweightCondition

Maridebart CafraglutideTreatment

Puerto Rico, United States45 locations

AmgenSponsor

Updated 2026-08-27 · NCT07575399See eligibility →

Recruiting nowPhase 1

Human Models of Selective Insulin Resistance: Alpelisib, Part I

Insulin Resistance, Prediabetic StateCondition

Alpelisib 300 mg, PlaceboTreatment

United States1 locations

Columbia UniversitySponsor

Updated 2026-08-24 · NCT06354088See eligibility →

Recruiting nowPhase 4

Incretin Therapies in Obesity-related HFpEF

Heart Failure, Diastolic, Heart Failure With Preserved Ejection FractionCondition

TirzepatideTreatment

United States1 locations

Columbia UniversitySponsor

Updated 2026-08-24 · NCT07554638See eligibility →

Recruiting nowPhase 2

Atomoxetine in Melanocortin Obesity Syndrome

Melanocortin Obesity Syndrome, MCOSCondition

Atomoxetine, PlaceboTreatment

United States3 locations

Icahn School of Medicine at Mount SinaiSponsor

Updated 2026-08-07 · NCT06899178See eligibility →

Recruiting nowPhase 4

Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

Obesity (Disorder), Breast CancerCondition

TirzepatideTreatment

United States1 locations

Weill Medical College of Cornell UniversitySponsor

Updated 2026-07-22 · NCT07257484See eligibility →

Recruiting nowPhase 1

Effect of Insulin Lowering on Lipogenesis

Hyperinsulinemia, Insulin ResistanceCondition

Placebo, Diazoxide Oral Suspension, 2 mg per kg per doseTreatment

United States1 locations

Columbia UniversitySponsor

Updated 2026-07-06 · NCT07403604See eligibility →

Recruiting nowNot applicable

A Study to Investigate Why Overweight People Regain Weight After Losing Weight in a Behavioral Weight Loss Program

ObesityCondition

Weight lossTreatment

United States3 locations

University of PittsburghSponsor

Updated 2026-06-12 · NCT05748158See eligibility →

Recruiting nowPhase 4

Weight Loss Study: Genetics and Response to Naltrexone/Bupropion

ObesityCondition

Naltrexone-Bupropion CombinationTreatment

United States1 locations

Columbia UniversitySponsor

Updated 2026-06-10 · NCT05919797See eligibility →

Recruiting nowPhase 2

Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease

Crohn Disease (CD)Condition

Tirzepatide, Standard of care treatmentTreatment

United States3 locations

Washington University School of MedicineSponsor

Updated 2026-06-05 · NCT06976853See eligibility →

Recruiting nowNot applicable

Impact of Yo-Yo Sleep on Cardiometabolic Health

Cardiometabolic Syndrome, ObesityCondition

Intermittent Short Sleep (ISS), Social Jetlag (SJL)Treatment

United States1 locations

Columbia UniversitySponsor

Updated 2026-05-18 · NCT05880758See eligibility →

Recruiting nowNot applicable

Endoscopic Bariatric Therapies (EBTs): A Retrospective and Prospective Multicenter Registry

Obesity, Weight LossCondition

Endoscopic Bariatric TherapiesTreatment

United States1 locations

Weill Medical College of Cornell UniversitySponsor

Updated 2026-04-23 · NCT04494048See eligibility →

Recruiting nowPhase 3

A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

Nausea and Vomiting, ObesityCondition

Tradipitant, PlaceboTreatment

United States10 locations

Vanda PharmaceuticalsSponsor

Updated 2026-04-20 · NCT07446439See eligibility →

Recruiting nowNot applicable

Family COMIDA (Consumo de Opciones Más Ideales De Alimentos) (Eating More Ideal Food Options)

Obesity, Child ObesityCondition

Parent Weekly Individual Telephone Support, Child EducationTreatment

United States1 locations

Memorial Sloan Kettering Cancer CenterSponsor

Updated 2026-04-15 · NCT07144800See eligibility →

Recruiting nowNot applicable

Mothers' Action Project for Child Health

Dental Caries, Obesity RiskCondition

health education and social network building, dental referral and educational materialsTreatment

United States1 locations

University of Massachusetts, WorcesterSponsor

Updated 2026-04-14 · NCT06753669See eligibility →

Recruiting nowPhase 4

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

Type2Diabetes, ASCVDCondition

SGLT2 inhibitor, GLP-1 receptor agonistTreatment

United States36 locations

Brigham and Women's HospitalSponsor

Updated 2026-04-13 · NCT05390892See eligibility →

Recruiting nowEarly Phase 1

A Study of a Weight Loss Intervention in People With Endometrial Cancer

Endometrial CancerCondition

TirzepatideTreatment

United States7 locations

Memorial Sloan Kettering Cancer CenterSponsor

Updated 2026-04-13 · NCT06751589See eligibility →

Recruiting nowNot applicable

Reducing Obesity Using Social Ties Program

ObesityCondition

Social Network Intervention, Individual Lifestyle InterventionTreatment

United States1 locations

Weill Medical College of Cornell UniversitySponsor

Updated 2026-04-01 · NCT06335810See eligibility →

Recruiting nowNot applicable

CHIME: Comparing Health Interventions for Maternal Equity

Obesity and Overweight, NutritionCondition

Self-Management, Community-BasedTreatment

United States4 locations

Stanford UniversitySponsor

Updated 2026-03-05 · NCT06724172See eligibility →

Recruiting nowNot applicable

Food FARMacia: Reducing Childhood Obesity in Households With Food Insecurity

Nutrition, HealthyCondition

Food FARMacia Program, Self-directed meal preparation supportTreatment

United States2 locations

Stanford UniversitySponsor

Updated 2026-03-05 · NCT06051591See eligibility →

Recruiting nowPhase 3

A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic FormCondition

Setmelanotide, PlaceboTreatment

United Kingdom, United States11 locations

Rhythm Pharmaceuticals, Inc.Sponsor

Updated 2026-02-12 · NCT06760546See eligibility →

Recruiting nowNot applicable

Comparing the Efficacy and Safety of the EndoZip System and Apollo ESG in Obese Patients

Obesity, OverweightCondition

EndoZip System, OverStitch Endoscopic Suturing System (ESG)Treatment

United States2 locations

Nitinotes Surgical Ltd.Sponsor

Updated 2026-01-21 · NCT07090005See eligibility →

Recruiting nowNot applicable

Time Restricted Eating for WeIght LoSs MainTenance-2

Weight Loss, Weight GainCondition

TRE, Weight-Loss Maintenance AdviceTreatment

United States1 locations

NYU Langone HealthSponsor

Updated 2025-12-26 · NCT07190170See eligibility →

Recruiting nowNot applicable

High Fructose Diet, the Gut Microbiome, and Metabolic Health

MASLD, Type 2 DiabetesCondition

Fructose, glucoseTreatment

United States1 locations

Icahn School of Medicine at Mount SinaiSponsor

Updated 2025-12-17 · NCT06329544See eligibility →

Recruiting nowNot applicable

Study to Investigate Genetic Causes of Severe Early Childhood Onset Obesity.

ObesityCondition

Intervention not listedTreatment

United States2 locations

Columbia UniversitySponsor

Updated 2025-10-21 · NCT01998750See eligibility →

Recruiting nowNot applicable

Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

Childhood Obesity, Morbid ObesityCondition

Transcriptome profilingTreatment

United States2 locations

Columbia UniversitySponsor

Updated 2025-10-21 · NCT02602769See eligibility →

Recruiting nowNot applicable

A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors

Acute Lymphoblastic Leukemia, ObesityCondition

PEDALL, Standard of careTreatment

United States1 locations

Columbia UniversitySponsor

Updated 2025-10-07 · NCT05963971See eligibility →

Recruiting nowNot applicable

Effects of Ultra Processed Food on Intestinal Energy Harvest

Obesity and OverweightCondition

Diet containing 80% ultra processed foods, Diet containing 20% ultra processed foodsTreatment

United States1 locations

Columbia UniversitySponsor

Updated 2025-10-03 · NCT06853288See eligibility →

Recruiting nowNot applicable

Circadian Misalignment and Energy Balance

ObesityCondition

Meal timesTreatment

United States1 locations

Columbia UniversitySponsor

Updated 2025-09-09 · NCT03663530See eligibility →

Recruiting nowNot applicable

Intervention INC: An Interactive Family-centered mHealth Tool to Reduce Obesity Risk in Urban Minority Preadolescents

Obesity, ChildhoodCondition

Web-based comic and newsletters, Didactic health informationTreatment

United States2 locations

Tufts UniversitySponsor

Updated 2025-04-10 · NCT05935592See eligibility →

Recruiting nowNot applicable

Chronic Widespread Pain After Rapid Weight Loss in Non-Hispanic Black and Hispanic/Latino/a/x Adults

Chronic Pain, Widespread, ObesityCondition

Bariatric SurgeryTreatment

United States3 locations

New York UniversitySponsor

Updated 2025-01-28 · NCT06795386See eligibility →

Recruiting nowNot applicable

RESET System Pivotal Trial (Rev F)

Diabetes type2, ObesityCondition

RESET Liner, ShamTreatment

United States7 locations

Morphic Medical Inc.Sponsor

Updated 2024-07-18 · NCT04101669See eligibility →

Opening soonPhase 3

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

Overweight, ObesityCondition

zenagamtide, PlaceboTreatment

United States37 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07720271See eligibility →

Opening soonNot applicable

High-protein plUs reSistance Training in gLucagon-like pEptide 1 Receptor Agonist Users (HUSTLE)

Weight LossCondition

High protein diet, Resistance Training (RT) ProgramsTreatment

United States1 locations

NYU Langone HealthSponsor

Updated 2026-07-13 · NCT07700030See eligibility →

Opening soonNot applicable

AIManage Using an AI-driven CDS and Chatbot

Diabetes, ObesityCondition

AIManageTreatment

United States1 locations

NYU Langone HealthSponsor

Updated 2026-04-22 · NCT07546357See eligibility →

Opening soonPhase 2

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

Obesity and OverweightCondition

NA-931, TirzepatideTreatment

Australia, New Zealand17 locations

Biomed Industries, Inc.Sponsor

Updated 2026-03-27 · NCT06732245See eligibility →

Opening soonPhase 1

Human Models of Selective Insulin Resistance: Pancreatic Clamp

Insulin Resistance, HyperinsulinemiaCondition

Insulin human, Octreotide AcetateTreatment

United States1 locations

Columbia UniversitySponsor

Updated 2026-02-06 · NCT06558422See eligibility →

Opening soonNot applicable

Gastric Ultrasound in Patients Who Have Undergone Bariatric Surgery

Obesity, Weight LossCondition

Gastric Point of Care UltrasoundTreatment

United States1 locations

Icahn School of Medicine at Mount SinaiSponsor

Updated 2025-12-30 · NCT07310875See eligibility →

Invitation onlyPhase 2

Consumption of More Ideal Food Options (COMIDA: Consumo de Opciones Más Ideales De Alimentos)

Overweight, ObesityCondition

Initial in-person individual diet and exercise counseling (N vs. Y), Thrice weekly diet and exercise text messages (N vs. Y)Treatment

United States1 locations

Memorial Sloan Kettering Cancer CenterSponsor

Updated 2026-07-06 · NCT03851458See eligibility →

Invitation onlyPhase 2

A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)

Hypothalamic ObesityCondition

BivamelagonTreatment

United Kingdom, United States9 locations

Rhythm Pharmaceuticals, Inc.Sponsor

Updated 2026-02-10 · NCT07156578See eligibility →

Invitation onlyEarly Phase 1

Truway Diagnostic Tools in Primary Care

Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, OverweightCondition

Truway Portable Ultrasound Device, Truway Blood Glucose MonitorTreatment

United States1 locations

Truway Health, Inc.Sponsor

Updated 2025-10-24 · NCT07209527See eligibility →

Active, not recruitingPhase 2

Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

Obesity & Overweight, Mobility DisabilityCondition

Enobosarm, Semaglutide (Wegovy) weekly injectionTreatment

United States13 locations

Veru Inc.Sponsor

Updated 2026-09-04 · NCT07446998See eligibility →

Active, not recruitingNot applicable

Long Term Outcomes of Bariatric Patients Treated With Surgery or Endoscopy

GERD, ObesityCondition

Endoscopy, SurgeryTreatment

United States6 locations

Johns Hopkins UniversitySponsor

Updated 2026-08-21 · NCT03705416See eligibility →

Active, not recruitingPhase 3

A Trial of Setmelanotide in Acquired Hypothalamic Obesity

Hypothalamic ObesityCondition

Setmelanotide, PlaceboTreatment

Canada, Germany28 locations

Rhythm Pharmaceuticals, Inc.Sponsor

Updated 2026-08-10 · NCT05774756See eligibility →

Active, not recruitingPhase 2

A Study of the Body's Response to Exercise and a Plant-Based Diet in Overweight Postmenopausal Women With Breast Cancer

Breast Cancer, Primary Hormone Receptor Positive Breast CancerCondition

Exercise Treatment, Plant-Based DietTreatment

United States7 locations

Memorial Sloan Kettering Cancer CenterSponsor

Updated 2026-06-17 · NCT04298086See eligibility →

Active, not recruitingNot applicable

Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer

Prostate CancerCondition

Whole-food, Plant-Based Diet, General Nutritional CounselingTreatment

United States3 locations

Weill Medical College of Cornell UniversitySponsor

Updated 2026-06-16 · NCT05471414See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

Obesity, OverweightCondition

RetatrutideTreatment

Argentina, Canada35 locations

Eli Lilly and CompanySponsor

Updated 2026-06-09 · NCT07357415See eligibility →

Active, not recruitingNot applicable

NYUCI-ES: Psychosocial Intervention to Improve Health Outcomes for Chinese and Korean ADRD Caregivers

Dementia Caregivers, DiabetesCondition

Treatment GroupTreatment

United States1 locations

New York UniversitySponsor

Updated 2026-06-03 · NCT05461495See eligibility →

Active, not recruitingNot applicable

Low GI Diet in Children and Adolescents With ALL

Acute Lymphoblastic Leukemia, Pediatric, Obesity, PediatricCondition

Low Glycemic Index DietTreatment

United States5 locations

Columbia UniversitySponsor

Updated 2026-05-29 · NCT03157323See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

Obesity, OverweightCondition

Retatrutide, PlaceboTreatment

United Kingdom, United States31 locations

Eli Lilly and CompanySponsor

Updated 2026-04-17 · NCT07232719See eligibility →

Active, not recruitingNot applicable

Thermogenic Silencer Regulatory Factors in Humans

Obesity, Metabolic DiseaseCondition

Cold Vest Exposure Period, Rewarming Exposure PeriodTreatment

United States1 locations

Rockefeller UniversitySponsor

Updated 2026-04-14 · NCT06424132See eligibility →

Active, not recruitingNot applicable

Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide

Obesity, Weight Change TrajectoryCondition

Revita Duodenal Mucosal Resurfacing (DMR), ShamTreatment

United States32 locations

Fractyl Health Inc.Sponsor

Updated 2026-03-03 · NCT06484114See eligibility →

Active, not recruitingPhase 2

Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo

ObesityCondition

Nimacimab injection, Nimacimab placebo injectionTreatment

United States16 locations

Skye Bioscience, Inc.Sponsor

Updated 2026-01-14 · NCT06577090See eligibility →

Active, not recruitingNot applicable

A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple MyelomaCondition

Plant based mealsTreatment

United States7 locations

Memorial Sloan Kettering Cancer CenterSponsor

Updated 2025-09-09 · NCT04920084See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near New York, United States

Current studies

Related cities